Undisclosed CEACAM5-MMAE CAPAC / Shasqi - LARVOL DELTA

Tumor-selective MMAE activation via CEACAM5 pre-targeting using click chemistry: A first-in-class strategy to enhance clinical benefit in targeted therapy (ESMO 2025) - "By decoupling targeting from payload delivery, this approach minimizes off-target toxicity, enabling higher dosing and the potential for greater clinical benefit. Legal entity responsible for the study Shasqi, Inc."

Clinical • Gastric Cancer • Oncology • Pancreatic Cancer • CEACAM5

CEACAM5 pre-targeting via click chemistry enables tumor-selective MMAE activation: A first-in-class approach to enhance clinical benefit in targeted therapy (AACR-NCI-EORTC 2025) - "It demonstrates robust anti-tumor efficacy in multiple tumor models, including large tumors, and a favorable tolerability profile. By decoupling targeting from payload delivery, this approach minimizes off-target toxicity, enabling higher dosing and the potential for greater clinical benefit."

Clinical • Late-breaking abstract • Gastric Cancer • Oncology • Pancreatic Cancer • CEACAM5